文献速递免疫规划

基于乙肝病毒串联核心颗粒展示多种保守抗原的甲型流感病毒病毒样颗粒候选疫苗

A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
PubMed 文献 · Vaccine · 2018-01-03

研究利用乙肝病毒串联核心平台构建含基质蛋白2胞外域和血凝素茎部4种保守抗原的病毒样颗粒疫苗Tandiflu1,免疫后诱导可结合H1、H5、H11、H9、H16及基质蛋白2保守表位的交叉反应抗体,对H1N1致死攻击提供100%保护,血清转移可保护未免疫小鼠。

要点

  • Tandiflu1含基质蛋白2胞外域和血凝素茎部4种保守抗原。
  • 免疫诱导抗体可结合H1、H5、H11、H9、H16及基质蛋白2保守表位。
  • H1N1致死攻击后Tandiflu1免疫组保护率为100%。

核心结论

  • 基于串联核心的甲型流感病毒疫苗可能对引起季节性及大流行的常见和新兴H1甲型流感病毒提供广泛保护。

研究设计与样本

  • 研究利用乙肝病毒串联核心平台构建含多种保守抗原的病毒样颗粒疫苗候选Tandiflu1,并在动物模型中评估免疫原性和保护效果。

主要发现

  • Tandiflu1免疫诱导的多克隆抗体可结合甲型流感病毒第1组血凝素H1、H5、H11、H9、H16及多数甲型流感病毒株表达的基质蛋白2保守表位。
  • Tandiflu1免疫对H1N1甲型流感病毒致死攻击提供100%保护。
  • 从免疫动物转移血清足以使未免疫小鼠免于流感相关疾病。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Existing Influenza A virus (IAV) vaccines target variable parts of the virus that may change between seasons. Vaccine design relies on predicting the predominant circulating influenza strains but when there is a mismatch between vaccine and circulating strains, efficacy is sub-optimal. Furthermore, current approaches provide limited protection against emerging influenza strains that may cause pandemics. One solution is to design vaccines that target conserved protein domains of influenza, which remain largely unchanged over time and are likely to be found in emergent variants. We present a virus-like particle (VLP), built using the hepatitis B virus tandem core platform, as an IAV vaccine candidate containing multiple conserved antigens. Hepatitis B core protein spontaneously assembles into a VLP that is immunogenic and confers immunogenicity to proteins incorporated into the major insertion region (MIR) of core monomers. However, insertion of antigen sequences may disrupt particle assembly preventing VLP formation or result in unstable particles. We have overcome these problems by genetically manipulating the hepatitis B core to express core monomers in tandem, ligated with a flexible linker, incorporating different antigens at each of the MIRs. Immunisation with this VLP, named Tandiflu1, containing 4 conserved antigens from matrix protein 2 ectodomain and hemagglutinin stalk, leads to production of cross-reactive and protective antibodies. The polyclonal antibodies induced by Tandiflu1 can bind IAV Group 1 hemagglutinin types H1, H5, H11, H9, H16 and a conserved epitope on matrix protein 2 expressed by most strains of IAV. Vaccination with Tandiflu1 results in 100% protection from a lethal influenza challenge with H1N1 IAV. Serum transfer from vaccinated animals is sufficient to confer protection from influenza-associated illness in naïve mice. These data suggest that a Tandem Core based IAV vaccine might provide broad protection against common and emergent H1 IAV strains responsible for seasonal and pandemic influenza in man.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ramirez A, Morris S, Maucourant S, et al. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles. Vaccine. 2018. PMID: 29306508. doi:10.1016/j.vaccine.2017.12.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。